Susceptibility Testing for Piperacillin-Tazobactam (JCM ed.)
Editors in Conversation
English - April 08, 2023 07:34 - 49 minutes - 34.1 MB - ★★★★ - 10 ratingsLife Sciences Science Health & Fitness Medicine asm for fox interviews jeff magazine microbe microbiology news science Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Susceptibility testing for piperacillin-tazobactam has undergone rapid evolution, largely driven by some surprising results from the MERINO trial, which compared the efficacy of piperacillin-tazobactam and meropenem for treatment of patients with ceftriaxone-resistant E. coli or Klebsiella pneumoniae bacteremia. We discuss how the results of the MERINO trial led to reconsideration of breakpoints for pipercillin-tazobactam at the Clinical Laboratory Standards Institute, or CLSI, how the breakpoints were changed, and how well commercial platforms perform piperacillin-tazobactam testing using FDA or CLSI breakpoints. Spoiler alert: the news isn’t great.
If you are interested in beta-lactam/beta lactamase combinations, you should check out the previous episode of this podcast, hosted by our friend Dr. Cesar Arias, the Editor-in-Chief of Antimicrobial Agents and Chemotherapy. Cesar and the guests did a great review of recent developments in this fast-moving area.